Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 16/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 12/20 | 0.42 |
| ▸ | ITGAV | P06756 | 5/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7032219 | 0.98 | ITGB3 (0.40) | ITGB3ITGA2BITGAVITGB1SMN1; SMN2 | |
| SCHEMBL7038261 | 0.98 | ITGB3 (0.40) | ITGB3ITGA2BITGAVITGB1SMN1; SMN2 | |
| SCHEMBL7038923 | 0.96 | ITGB3 (0.40) | ITGB3ITGA2BITGAVEGLN2EGLN1 | |
| SCHEMBL7032427 | 0.93 | ITGB3 (0.41) | ITGB3ITGA2BITGAVEGLN2EGLN1 | |
| SCHEMBL7036629 | 0.90 | EGLN2 (0.39) | ITGB3ITGA2BITGAVEGLN2EGLN1 | |
| SCHEMBL7030553 | 0.90 | ITGB3 (0.46) | ITGB3ITGA2BITGAVEGLN2EGLN1 | |
| SCHEMBL7031372 | 0.90 | ITGB1 (0.39) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL7383429 | 0.89 | FOLH1 (0.39) | ITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL7035435 | 0.89 | ITGB3 (0.40) | ITGB3ITGA2BITGAVEGLN2EGLN1 | |
| SCHEMBL7035290 | 0.89 | ITGB3 (0.51) | ITGB3ITGA2BITGAVEGLN2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-10-02 | — | — | US | claimed |
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-10-02 | — | — | US | disclosed |
| WO-1999052879-A1 | ACYLRESORCINOL DERIVATIVES AS SELECTIVE VITRONECTIN RECEPTOR INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | ASGR1, TEK, APLNR | ITGB3 403/4885ITGA2B 573/4885ITGAV 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.